Skip to content

Study · Not a test of the peptide alone · 1995

5 results

Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.

Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P

European journal of cancer (Oxford, England : 1990)1 Dec 1995Cited by 28 (Europe PMC)

PMID8652276 (opens in a new tab)DOI10.1016/0959-8049(95)00477-7 (opens in a new tab)PepBankPUB-08652276
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with advanced non-small cell lung cancer, a regimen of cisplatin, etoposide, thymosin alpha‑1 and interferon alpha 2a gave 24 responses (two complete, 22 partial) among 56 assessable patients.

    In plain wordsIn people with advanced lung cancer, a chemotherapy regimen that included thymosin alpha‑1 and interferon gave 24 responses among 56 assessable patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableObjective response
    Study

    n = 56

    Outcome group
    Tumor growth · Cancer

    Measurements

    Responses
    24 patients
    assessable patients

    Source sentences

    Summary
    There were 24 responses (two complete, 22 partial) among 56 assessable patients.
    1 context sentence
    Summary · context
    A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with advanced non-small cell lung cancer, median survival with the regimen of cisplatin, etoposide, thymosin alpha‑1 and interferon alpha 2a was 12.6 months.

    In plain wordsIn people with advanced lung cancer, median survival on a regimen that included thymosin alpha‑1 and interferon was 12.6 months.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMedian survival
    Study

    n: not reported in source

    Outcome group
    Mortality · Cancer

    Measurements

    Median survival
    12.6 months
    regimen

    Source sentences

    Summary
    Median survival was 12.6 months.
    1 context sentence
    Summary · context
    A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In patients with advanced non-small cell lung cancer, the regimen of cisplatin, etoposide, thymosin alpha‑1 and interferon alpha 2a was reported as well tolerated overall.

    In plain wordsIn people with advanced lung cancer, a chemotherapy regimen that included thymosin alpha‑1 and interferon was reported as well tolerated.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOverall tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall, treatment was well tolerated.
    1 context sentence
    Summary · context
    A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with advanced non-small cell lung cancer, the depression of natural killer cell activity by chemotherapy was less prominent with thymosin alpha‑1 and interferon added than with cisplatin and etoposide only.

    In plain wordsIn people with advanced lung cancer, chemotherapy lowered natural killer cell activity less when thymosin alpha‑1 and interferon were added than with chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNatural killer cell activity
    Study

    n: not reported in source

    Comparator
    Cisplatin and etoposide only (concomitant group)
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Natural killer cell activity and lymphocyte subtypes were depressed by chemotherapy, but this effect was less prominent in patients receiving TA1 and IFN in comparison with a concomitant group of patients treated with DDP and VP-16 only
    1 context sentence
    Summary · context
    A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with advanced non-small cell lung cancer, the depression of lymphocyte subtypes by chemotherapy was less prominent with thymosin alpha‑1 and interferon added than with cisplatin and etoposide only.

    In plain wordsIn people with advanced lung cancer, chemotherapy lowered lymphocyte subtype counts less when thymosin alpha‑1 and interferon were added than with chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLymphocyte subtypes
    Study

    n: not reported in source

    Comparator
    Cisplatin and etoposide only (concomitant group)
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Natural killer cell activity and lymphocyte subtypes were depressed by chemotherapy, but this effect was less prominent in patients receiving TA1 and IFN in comparison with a concomitant group of patients treated with DDP and VP-16 only
    1 context sentence
    Summary · context
    A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.